Banking for Bioassays
Analytical bioassay cell banks certainly have benefits. But with little guidance on how to get them up and running, it can be difficult to know what best practices to follow.
Mike Merges and Mike Sadick |
As technology advances, regulators are demanding ever-greater precision, accuracy and reproducibility of assays used during pharmaceutical development. The goal is clear: to ensure that the products ultimately delivered to patients are of high quality. Bioassays are an important component in ensuring regulatory compliance, and effective bioassays require reproducible cell lines; analytical bioassay cell banks are commonly used to provide the necessary cells.
There is a large amount of guidance – both regulations and standards – governing the production of GMP production cell banks, notably the ICH document Q5D on the derivation and characterization of cell substrates used for production of biotechnological and biological products (1). These will be serially sub-cultivated cells that are characterized by common starting sources for each production lot; in other words, they are preserved banks of cells. The guidance states that the identity, purity and stability of the parental cell line, and subsequent master and working cell banks, must be confirmed.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine